SNCA and Parkinson disease: Preclinical studies using induced pluripotent stem cell (iPSC)–derived neurons and other cellular models have demonstrated that chaperone treatment can rescue GCase function and lead to a significant reduction in α-synuclein aggregation, a key pathological hallmark of PD [60].